Septerna (SEPN) Stock: Buy, Sell, or Hold?
SEPN - Septerna, Inc. Common Stock
$40.88
0.12 (0.29%)
▲
5d:
+9.16%
30d:
+6.32%
90d:
+23.5%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When SEPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SEPN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SEPN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SEPN is currently trading at $40.88, which is considered extended relative to its 30-day fair value range of $36.83 to $39.61.
Technical Outlook: Technically, SEPN is in a uptrend. The price is approaching resistance at $41.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SEPN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $54.22 (+32.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SEPN is in a uptrend. The price is approaching resistance at $41.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SEPN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $54.22 (+32.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$36.83 -
$39.61
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.6% below Wall St target ($54.22)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$36.83 -
$39.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$34.36
Resistance Level
$41.77
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.06
Wall Street Target
$54.22
(+32.6%)
Revenue Growth (YoY)
22375.6%
Profit Margin
-24.5%
Share & Embed Analysis
Last updated: October 22, 2026 11:32 PM ET
Data refreshes hourly during market hours. Next update: 12:32 AM
Data refreshes hourly during market hours. Next update: 12:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 49 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 70 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 75 BUY |
